{
    "2018-04-04": [
        [
            {
                "time": "2018-04-04",
                "original_text": "泰格医药：预计一季度净利润同比增长1.85倍-2倍",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "净利润",
                        "同比增长",
                        "1.85倍-2倍"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-04",
                "original_text": "绩优+创新！医药行业妖股频出，这两点值得一看",
                "features": {
                    "keywords": [
                        "绩优",
                        "创新",
                        "医药行业",
                        "妖股"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-04",
                "original_text": "[推荐评级] 医药生物行业2018年二季度策略报告：把握政策利好 聚焦创新和龙头",
                "features": {
                    "keywords": [
                        "医药生物",
                        "政策利好",
                        "创新",
                        "龙头"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-04",
                "original_text": "[增持评级] 医药生物行业点评：国务院政策加码 医药行业供给侧改革提速",
                "features": {
                    "keywords": [
                        "医药生物",
                        "国务院",
                        "政策加码",
                        "供给侧改革"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-04",
                "original_text": "国务院发布仿制药鼓励政策 七股闻风而动",
                "features": {
                    "keywords": [
                        "国务院",
                        "仿制药",
                        "鼓励政策",
                        "七股"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}